Researcher in lab

Find clinical trials

Our clinical trial portfolio is one of the largest in the country. We have more than 700 clinical trials open across 30 clinical units.

Find Melbourne Sexual Health Centre research studies and clinical trials

Data source: Bayside Health Alfred Powertrials list of active trials
Last updated: 9 October 2026

Clear filter
681 clinical trials found
Clinical trials

CVAY736I12301 - VAYHIT1

A phase 3, randomized, double-blind study of ianalumab (VAY736) versus placebo in addition to first-line corticosteroids in primary immune thrombocytopenia (VAYHIT1) (NCT05653349)

Currently recruiting

CVAY736J12101

A phase Ib, multi-center, open-label dose escalation and expansion platform study of VAY736 as single agent and in combination with select antineoplastic agents in patients with non-Hodgkin Lymphoma (NHL) (NCT04903197)

No longer recruiting

CVAY736O12301 - VAYHIA

A phase 3, randomized, double-blind, study to assess efficacy and safety of ianalumab (VAY736) versus placebo in warm autoimmune hemolytic anemia (wAIHA) patients who failed at least one line of treatment (VAYHIA) (NCT05648968)

Currently recruiting

CVAY736Q12201

A phase 2 study to evaluate the efficacy and safety of ianalumab in patients with primary immune thrombocytopenia (ITP) previously treated with at least two lines of therapy (NCT05885555)

Currently recruiting

CYPRESS

A Phase 3, Multi-center, Randomized Withdrawal and Long-Term Extension Study of Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Participants with Multiple System Atrophy (NCT05696717)

No longer recruiting

CYTB323A12101

Phase I/II, open label, multicenter study of YTB323 in adult patients with CLL/SLL, 3L+ DLBCL, ALL and 1L HR LBCL (NCT03960840)

Currently recruiting

CYTB323L12201

A Phase 2, randomized, open-label, controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe refractory idiopathic inflammatory myopathies (NCT06665256)

The CYTB323L12201 study is designed to evaluate the safety and efficacy of rapcabtagene autoleucel (CAR-T) compared to standard of care treatment in participants with idiopathic inflammatory myopathies (IIM). Participants will be randomised into either a CAR-T infusion or a comparator option. After the end of study participants who received the CAR-T infusion will enter a long-term follow-up period lasting up to 15 years.

Currently recruiting

CYTB323N12101

An open-label, multi-center, phase 1/2 study to assess safety, efficacy, and cellular kinetics of YTB323 in participants with Relapsing Multiple Sclerosis with breakthrough disease activity during previous treatment with a highly efficacious therapy (NCT06617793)

Currently recruiting

CYTB323R12101

An open-label, multi-center, phase I/II study to assess safety, disease progression, and cellular kinetics following YTB323 administration in participants with non-active Progressive Multiple Sclerosis [PMS] (NCT06675864)

Currently recruiting

D7400C00006

A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of AZD0486, a Bispecific Antibody Targeting CD19 in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (NCT04594642)

Currently recruiting

D7405C00001

A Phase 1/2 Study to Evaluate the Safety and Efficacy of AZD0486 in Adolescent and Adult Participants with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia (NCT06137118)

Currently recruiting

DAISY STUDY

A Phase II, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate The Efficacy and Safety of DONQ52 in Active Celiac Disease Patients Who Have Duodenal Mucosal Damage and Persistent Symptoms Despite Attempting A Gluten-free Diet (NCT07239336)

This is a parallel-group, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of DONQ52 in active celiac disease (CeD) patients who have current duodenal mucosal damage and persistent symptoms despite attempting a gluten-free diet (GFD).
Currently recruiting

DAPA_HF

Mechanisms of action of SGLT2 inhibitors in patients with heart failure with reduced ejection fraction (HFrEF) (ACTRN12621000187842)

No longer recruiting

Daratumumab@Home

A phase 2 study of the feasibility and efficacy of at home patient administered subcutaneous daratumumab in patients with relapsed multiple myeloma (ACTRN12624001468516)

Currently recruiting

DASL-HiCaP

DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate [ANZUP1801]. A randomised phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localised prostate cancer.

A randomised phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localised prostate cancer. 
Currently recruiting

DB in asthma

Targeted treatment for people with dysfunctional breathing and difficult asthma (ACTRN12624001285549)

Currently recruiting

DB-1317-101

A Phase 1a/1b, Multicenter, Open-Label, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1317 in Participants with Selected Advanced/Metastatic Solid Tumors (NCT07141706)

This is a multicentre, open-label, multiple-dose, FIH Phase 1a/1b study. Phase 1a adopts an accelerated titration design and a BOIN design to identify the MTD or MAD of DB-1317; Phase 1b includes one randomized dose expansion cohort and two single-arm dose expansion cohorts to further evaluate the safety, tolerability and preliminary efficacy of DB-1317 in selected solid tumours and to identify optimal RP2D.
Currently recruiting

DCC-2618-04-001

Clinical Effectiveness of Ripretinib in Gastrointestinal Stromal Tumor [GIST]: Real-world Experience in Australia (Trial Not Registered)

This is a retrospective, observational, non-interventional, multi-center chart review study conducted in Australia.
Currently recruiting

DCD-HOPE

Hypothermic Oxygenated Perfusion (HOPE) in Donation after Circulatory Death (DCD) for Heart Transplantation (Registration Pending)

Currently recruiting

DECIDE

DExmedetomidine in Cardiac surgical Intraoperative Drug Evaluation (ACTRN12623001171606)

Currently recruiting
9 10 11 12 13